BCM
CRBU icon

Bronte Capital Management’s Caribou Biosciences CRBU Stock Holding History

Bronte Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,627
Closed -$29.7K – 59
2026
Q1 		$29.7K Hold
15,627
– – ﹤0.01% 47
2025
Q4 		$24.8K Buy
+15,627
New +$32.8K ﹤0.01% 39

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bronte Capital Management's CRBU Position: Q2 2026 in Review

Bronte Capital Management sold out of Caribou Biosciences (CRBU) in Q2 2026, closing a stake of 15,627 shares — an estimated $29.7K sold.

Bronte Capital Management first reported a position in CRBU in Q4 2025 and held it in 2 quarters. The position peaked at $29.7K in Q1 2026. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Bronte Capital Management reported no remaining Caribou Biosciences position as of Q2 2026 after selling out during the quarter.
  • Bronte Capital Management sold 15,627 Caribou Biosciences shares in Q2 2026, an estimated $29.7K.
  • Bronte Capital Management first reported a position in Caribou Biosciences in Q4 2025 and held it in 2 quarters.
  • Bronte Capital Management's Caribou Biosciences position peaked at $29.7K in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.